Rein Therapeutics (RNTX) Other financing activities (2016 - 2025)
Rein Therapeutics (RNTX) posted quarterly Other financing activities of $1.6 million for Q4 2025, down 77.33% year-over-year from $7.0 million in Q4 2024, and up 200.0% quarter-over-quarter from -$1.6 million in Q3 2025.
Rein Therapeutics (RNTX) Other financing activities (2016 - 2025) Analysis & Trends
Rein Therapeutics (RNTX) has reported Other financing activities for 8 consecutive years, with $1.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities fell 77.33% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 77.33% YoY), while the FY2025 annual figure was $1.6 million, down 77.31% from the prior year.
- Other financing activities climbed to $1.6 million in Q4 2025 per RNTX's latest filing, from -$1.6 million in the prior quarter.
- Across five years, Other financing activities topped out at $7.0 million in Q4 2024 and bottomed at -$1.6 million in Q3 2025.
- Historically, Other financing activities has averaged $961333.3 across 3 years, with a median of $26000.0 in 2021.
- On a YoY basis, Other financing activities climbed as much as 1478.22% in 2025 and fell as far as 1478.22% in 2025.
- Rein Therapeutics' Other financing activities stood at $1000.0 in 2021, then surged by 702900.0% to $7.0 million in 2024, then tumbled by 77.33% to $1.6 million in 2025.
- Business Quant data shows RNTX's Other financing activities at $1.6 million in Q4 2025, -$1.6 million in Q3 2025, and $1.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.59 Mn |
| Dec 31, 2025 | 1.59 Mn |
| Sep 30, 2025 | -1.59 Mn |
| Sep 30, 2025 | -1.59 Mn |
| Jun 30, 2025 | 1.59 Mn |
| Jun 30, 2025 | 1.59 Mn |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 7.03 Mn |
| Dec 31, 2024 | 7.03 Mn |
| Sep 30, 2024 | -101,000.00 |
| Sep 30, 2024 | -101,000.00 |
| Jun 30, 2024 | 101,000.00 |
| Jun 30, 2024 | 101,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Sep 30, 2021 | 26,000.00 |
| Sep 30, 2021 | 26,000.00 |
| Mar 31, 2020 | 552,000.00 |
| Mar 31, 2020 | 552,000.00 |